RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
An Open Label, Time-To-Event Continuous Reassessment Method, Phase I/II Study of the Mammalian Target of Rapamycin (mTOR) Inhibitor RAD001 in Combination With Imatinib (Gleevec) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) With Persistent Molecular Disease.
Study ID: UMCC 2008.093; Secondary ID: HUM 24993; Source: University of Michigan Cancer Center
Patients participating in this study will have a diagnosis of Chronic Myeloid Leukemia. This
study will evaluate whether the addition of an investigational drug called RAD001 given
together with Imatinib will better target leukemia stem cells, causing them to die. Stem
cells are a small population of cells, existing primarily within the bone marrow, and are
believed to be responsible for the ongoing risk of disease relapse.